Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #98 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 29 Oct 2025 | AJIT RAMKARAN SARDA | Bulk | Sell | 142,892 | 82.0200 | NSE |
| 29 Oct 2025 | AJIT RAMKARAN SARDA | Bulk | Buy | 265,483 | 81.5800 | NSE |
| 24 Oct 2025 | MATHEW CYRIAC | Bulk | Sell | 1,569,000 | 68.8400 | NSE |
| 24 Oct 2025 | ELIMATH ADVISORS PRIVATE LIMITED | Bulk | Buy | 1,497,124 | 68.7900 | NSE |
| 17 Jul 2025 | MATHEW CYRIAC | Bulk | Buy | 1,794,000 | 115.3100 | NSE |
| 17 Jul 2025 | ELIZABETH MATHEW | Bulk | Sell | 1,794,000 | 115.3100 | NSE |
| 13 Mar 2025 | MATHEW CYRIAC | Block | Sell | 3,995,324 | 81.7100 | BSE |
| 13 Mar 2025 | ELIZABETH MATHEW | Block | Buy | 3,995,324 | 81.7100 | BSE |
| 13 Mar 2025 | ELIZABETH MATHEW | Bulk | Buy | 3,995,324 | 81.7100 | BSE |
| 13 Mar 2025 | MATHEW CYRIAC | Bulk | Sell | 3,995,324 | 81.7100 | BSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 22 Dec 2022 | BONUS | Bonus 2:1 |
| 20 Jun 2024 | OTHER | Annual General Meeting |
| 3 Jul 2023 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 6 Aug 2026 | Financial Results | Yes |
| 19 May 2026 | Financial Results | Yes |
| 11 Feb 2026 | Financial Results | Yes |
| 21 Jan 2026 | Fund Raising | — |
| 12 Nov 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
